View in EDS

Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.

Saved in:
Bibliographic Details
Title: Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Authors: Pollom, Erqi L.1, Fujimoto, Dylann1, Wynne, Jacob1, Seiger, Kira1, Modlin, Leslie A.1, Jacobs, Lisa R.1, Azoulay, Melissa1,2, von Eyben, Rie1, Tupper, Laurie1, Gibbs, Iris C.1, Hancock, Steven L.1, Li, Gordon3, Chang, Steven D.3, Adler, John R.3, Harsh, Griffith R.3, Harraher, Ciara3, Nagpal, Seema3,4, Thomas, Reena P.3,4, Recht, Lawrence D.3,4, Choi, Clara Y.H.1,5
Source: International Journal of Radiation Oncology, Biology, Physics. May2017, Vol. 98 Issue 1, p123-130. 8p.
Subjects: Glioblastoma multiforme, Glioblastoma multiforme treatment, Stereotactic radiosurgery, Adjuvant treatment of cancer, Temozolomide, Quality of life, Diagnosis, Therapeutics, Antineoplastic agents, Brain tumors, Cancer relapse, Clinical trials, Combined modality therapy, Communication, Comparative studies, Gliomas, Longitudinal method, Research methodology, Medical cooperation, Questionnaires, Radiosurgery, Research, Research funding, Evaluation research, Treatment effectiveness, Disease progression, Kaplan-Meier estimator, Dacarbazine
Abstract: Purpose: We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide.Methods: HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) general, the EORTC quality of life questionnaire-brain cancer specific module (QLQ-BN20), and the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT). Questionnaires were completed at baseline and at every follow-up visit after completion of radiosurgery. Changes from baseline for 9 predefined HRQOL measures (global quality of life, physical functioning, social functioning, emotional functioning, motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty) were calculated at every time point.Results: With a median follow-up time of 10.4 months (range, 0.4-52 months), 139 total HRQOL questionnaires were completed by the 30 patients on trial. Compliance with HRQOL assessment was 76% at 12 months. Communication deficit significantly worsened over time, with a decline of 1.7 points per month (P=.008). No significant changes over time were detected in the other 8 scales of our primary analysis, including global quality of life. Although 8 patients (27%) experienced adverse radiation effects (ARE) on this dose escalation trial, it was not associated with a statistically significant decline in any of the primary HRQOL scales. Disease progression was associated with communication deficit, with patients experiencing an average worsening of 13.9 points per month after progression compared with 0.7 points per month before progression (P=.01).Conclusion: On this 5-fraction dose escalation protocol for newly diagnosed GBM, overall HRQOL remained stable and appears similar to historical controls of 30 fractions of radiation therapy. Tumor recurrence was associated with worsening communication deficit, and ARE did not correlate with a decline in HRQOL. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 122389364
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Pollom%2C+Erqi+L%2E%22">Pollom, Erqi L.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Fujimoto%2C+Dylann%22">Fujimoto, Dylann</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Wynne%2C+Jacob%22">Wynne, Jacob</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Seiger%2C+Kira%22">Seiger, Kira</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Modlin%2C+Leslie+A%2E%22">Modlin, Leslie A.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Jacobs%2C+Lisa+R%2E%22">Jacobs, Lisa R.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Azoulay%2C+Melissa%22">Azoulay, Melissa</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22von+Eyben%2C+Rie%22">von Eyben, Rie</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Tupper%2C+Laurie%22">Tupper, Laurie</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Gibbs%2C+Iris+C%2E%22">Gibbs, Iris C.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Hancock%2C+Steven+L%2E%22">Hancock, Steven L.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Li%2C+Gordon%22">Li, Gordon</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Chang%2C+Steven+D%2E%22">Chang, Steven D.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Adler%2C+John+R%2E%22">Adler, John R.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Harsh%2C+Griffith+R%2E%22">Harsh, Griffith R.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Harraher%2C+Ciara%22">Harraher, Ciara</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Nagpal%2C+Seema%22">Nagpal, Seema</searchLink><relatesTo>3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Thomas%2C+Reena+P%2E%22">Thomas, Reena P.</searchLink><relatesTo>3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Recht%2C+Lawrence+D%2E%22">Recht, Lawrence D.</searchLink><relatesTo>3,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Choi%2C+Clara+Y%2EH%2E%22">Choi, Clara Y.H.</searchLink><relatesTo>1,5</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22International+Journal+of+Radiation+Oncology%2C+Biology%2C+Physics%22">International Journal of Radiation Oncology, Biology, Physics</searchLink>. May2017, Vol. 98 Issue 1, p123-130. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Glioblastoma+multiforme%22">Glioblastoma multiforme</searchLink><br /><searchLink fieldCode="DE" term="%22Glioblastoma+multiforme+treatment%22">Glioblastoma multiforme treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Stereotactic+radiosurgery%22">Stereotactic radiosurgery</searchLink><br /><searchLink fieldCode="DE" term="%22Adjuvant+treatment+of+cancer%22">Adjuvant treatment of cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Temozolomide%22">Temozolomide</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink><br /><searchLink fieldCode="DE" term="%22Diagnosis%22">Diagnosis</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+agents%22">Antineoplastic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Brain+tumors%22">Brain tumors</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+relapse%22">Cancer relapse</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Combined+modality+therapy%22">Combined modality therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Communication%22">Communication</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Gliomas%22">Gliomas</searchLink><br /><searchLink fieldCode="DE" term="%22Longitudinal+method%22">Longitudinal method</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Questionnaires%22">Questionnaires</searchLink><br /><searchLink fieldCode="DE" term="%22Radiosurgery%22">Radiosurgery</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+progression%22">Disease progression</searchLink><br /><searchLink fieldCode="DE" term="%22Kaplan-Meier+estimator%22">Kaplan-Meier estimator</searchLink><br /><searchLink fieldCode="DE" term="%22Dacarbazine%22">Dacarbazine</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Purpose: </bold>We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide.<bold>Methods: </bold>HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) general, the EORTC quality of life questionnaire-brain cancer specific module (QLQ-BN20), and the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT). Questionnaires were completed at baseline and at every follow-up visit after completion of radiosurgery. Changes from baseline for 9 predefined HRQOL measures (global quality of life, physical functioning, social functioning, emotional functioning, motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty) were calculated at every time point.<bold>Results: </bold>With a median follow-up time of 10.4 months (range, 0.4-52 months), 139 total HRQOL questionnaires were completed by the 30 patients on trial. Compliance with HRQOL assessment was 76% at 12 months. Communication deficit significantly worsened over time, with a decline of 1.7 points per month (P=.008). No significant changes over time were detected in the other 8 scales of our primary analysis, including global quality of life. Although 8 patients (27%) experienced adverse radiation effects (ARE) on this dose escalation trial, it was not associated with a statistically significant decline in any of the primary HRQOL scales. Disease progression was associated with communication deficit, with patients experiencing an average worsening of 13.9 points per month after progression compared with 0.7 points per month before progression (P=.01).<bold>Conclusion: </bold>On this 5-fraction dose escalation protocol for newly diagnosed GBM, overall HRQOL remained stable and appears similar to historical controls of 30 fractions of radiation therapy. Tumor recurrence was associated with worsening communication deficit, and ARE did not correlate with a decline in HRQOL. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=122389364
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ijrobp.2017.01.242
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 123
    Subjects:
      – SubjectFull: Glioblastoma multiforme
        Type: general
      – SubjectFull: Glioblastoma multiforme treatment
        Type: general
      – SubjectFull: Stereotactic radiosurgery
        Type: general
      – SubjectFull: Adjuvant treatment of cancer
        Type: general
      – SubjectFull: Temozolomide
        Type: general
      – SubjectFull: Quality of life
        Type: general
      – SubjectFull: Diagnosis
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: Antineoplastic agents
        Type: general
      – SubjectFull: Brain tumors
        Type: general
      – SubjectFull: Cancer relapse
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Combined modality therapy
        Type: general
      – SubjectFull: Communication
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Gliomas
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Questionnaires
        Type: general
      – SubjectFull: Radiosurgery
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Disease progression
        Type: general
      – SubjectFull: Kaplan-Meier estimator
        Type: general
      – SubjectFull: Dacarbazine
        Type: general
    Titles:
      – TitleFull: Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pollom, Erqi L.
      – PersonEntity:
          Name:
            NameFull: Fujimoto, Dylann
      – PersonEntity:
          Name:
            NameFull: Wynne, Jacob
      – PersonEntity:
          Name:
            NameFull: Seiger, Kira
      – PersonEntity:
          Name:
            NameFull: Modlin, Leslie A.
      – PersonEntity:
          Name:
            NameFull: Jacobs, Lisa R.
      – PersonEntity:
          Name:
            NameFull: Azoulay, Melissa
      – PersonEntity:
          Name:
            NameFull: von Eyben, Rie
      – PersonEntity:
          Name:
            NameFull: Tupper, Laurie
      – PersonEntity:
          Name:
            NameFull: Gibbs, Iris C.
      – PersonEntity:
          Name:
            NameFull: Hancock, Steven L.
      – PersonEntity:
          Name:
            NameFull: Li, Gordon
      – PersonEntity:
          Name:
            NameFull: Chang, Steven D.
      – PersonEntity:
          Name:
            NameFull: Adler, John R.
      – PersonEntity:
          Name:
            NameFull: Harsh, Griffith R.
      – PersonEntity:
          Name:
            NameFull: Harraher, Ciara
      – PersonEntity:
          Name:
            NameFull: Nagpal, Seema
      – PersonEntity:
          Name:
            NameFull: Thomas, Reena P.
      – PersonEntity:
          Name:
            NameFull: Recht, Lawrence D.
      – PersonEntity:
          Name:
            NameFull: Choi, Clara Y.H.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2017
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 03603016
          Numbering:
            – Type: volume
              Value: 98
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: International Journal of Radiation Oncology, Biology, Physics
              Type: main
ResultId 1